NCT06143709Active, not recruiting
Precision PCI Registry
Precision Antiplatelet Therapy After Percutaneous Coronary Intervention Registry
Source: ClinicalTrials.gov · Last updated 18 Aug 2026
Brief summary (registry, in English)
The feasibility and clinical benefit of using a patient's genotype to guide antiplatelet therapy prescribing has been demonstrated. However, a more precise understanding of who to genotype, what to include on a genetic testing panel, and how to change antiplatelet therapy based on genotype results and other patient-specific factors is needed to optimize the impact of genotype-guided antiplatelet therapy on patient outcomes. The Precision PCI registry is a collaboration between the University of Florida, Gainesville and Jacksonville, USA, the University of North Carolina, Chapel Hill, USA, and University of Maryland, Baltimore, USA. This registry will include a diverse population of patients who undergo Percutaneous Coronary Intervention and clinical CYP2C19 genotyping, assess clinical outcomes over 12 months and collect DNA samples for additional genotyping, and conduct pharmacodynamic analysis of platelet function in a subset of patients. Objectives of the study: 1. Define the influence of African ancestry and other patient-specific factors on clinical outcomes with genotype-guided antiplatelet therapy following PCI in a real-world setting 2. Evaluate the safety and effectiveness of genotype-guided de-escalation of antiplatelet therapy (i.e., switching to less potent antiplatelet therapy) after PCI in a real-world setting 3. Elucidate the effect(s) of genotypes beyond CYP2C19 on platelet reactivity and clinical outcomes with clopidogrel after PCI
- Status (registry)
- Active, not recruiting
- Study type
- Observational
- Enrollment
- 1643 (actual)
- First submitted
- 16 Nov 2023
- Start date
- 17 Jul 2020
- Primary completion date
- 30 Jun 2027
- Lead sponsor
- University of Florida
- Diseases
- Coronary artery disease
- NCT number
- NCT06143709
What you commit to
- Study type: Observational
- Participants enrolled: 1643
- From 17 Jul 2020 to the primary completion date, 30 Jun 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Treated with thrombolysis within 48 hours
Other
- Managed surgically
Who the study is looking for
- Age ≥18 years
- Underwent percutaneous coronary intervention for any indication
- Had clinical CYP2C19 genotyping
- Treated with dual antiplatelet therapy including clopidogrel, prasugrel, or ticagrelor plus aspirin or
- Treated with a combination of a P2Y12 inhibitor i.e. clopidogrel, prasugrel or ticagrelor plus an oral anticoagulant.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University of Florida Coordinator of this site? Confirm its status | Gainesville | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.